Prosecution Insights
Last updated: May 29, 2026

Remix Therapeutics Inc.

8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready

Portfolio Summary

8
Total Pending OAs
2
Non-Final OAs
5
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (38%)
1
Easy (12%)
4
Unknown (50%)

Rejection Statute Mix

BucketCases
§102 only2 (25%)
§112 only1 (12%)
Double-patenting + other1 (12%)
No statute on record4 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHONG, KIMBERLY 1 72.4% +12.7%
MCDOWELL, BRIAN E 1 74.3% +30.6%
MOORE, SUSANNA 1 68.1% +31.8%
KUCKLA, ANNA GRACE 1 51.3% +52.1%
NESTOR, DONNA MICHELLE 1 57.5% +43.9%
BELL, SARA ELIZABETH 1 73.5% +39.9%
COUGHLIN, MATTHEW P 1 71.3% +11.8%
NOTTINGHAM, KYLE GREGORY 1 60.8% +33.8%

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18014059 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE MCDOWELL, BRIAN E 87d overdue
17917734 COMPOUNDS AND METHODS FOR MODULATING SPLICING BELL, SARA ELIZABETH 56d overdue
17917729 COMPOUNDS AND METHODS FOR MODULATING SPLICING NESTOR, DONNA MICHELLE 23d overdue
17802827 COMPOUNDS AND METHODS FOR MODULATING SPLICING COUGHLIN, MATTHEW P 8d overdue
18033748 OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING CHONG, KIMBERLY 5d overdue
17917842 COMPOUNDS AND METHODS FOR MODULATING SPLICING KUCKLA, ANNA GRACE 6d
17802863 COMPOUNDS AND METHODS FOR MODULATING SPLICING NOTTINGHAM, KYLE GREGORY 30d
18014057 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES MOORE, SUSANNA 78d

Top Art Units

Art UnitApps
1624 2
1626 2
1636 1
1627 1
1625 1
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18033748 OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING CHONG, KIMBERLY 1636 §112 Non-Final OA 5d overdue Pending Apr 25, 2023
18014059 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE MCDOWELL, BRIAN E 1624 §102 Non-Final OA 87d overdue Pending Dec 30, 2022
18014057 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES MOORE, SUSANNA 1624 DPOther Final Rejection 78d Pending Dec 30, 2022
17917842 COMPOUNDS AND METHODS FOR MODULATING SPLICING KUCKLA, ANNA GRACE 1626 Other Final Rejection 6d Pending Oct 07, 2022
17917729 COMPOUNDS AND METHODS FOR MODULATING SPLICING NESTOR, DONNA MICHELLE 1627 Other Final Rejection 23d overdue Pending Oct 07, 2022
17917734 COMPOUNDS AND METHODS FOR MODULATING SPLICING BELL, SARA ELIZABETH 1625 §102 Non-Final OA 56d overdue Pending Oct 07, 2022
17802827 COMPOUNDS AND METHODS FOR MODULATING SPLICING COUGHLIN, MATTHEW P 1626 Other Final Rejection 8d overdue Pending Aug 26, 2022
17802863 COMPOUNDS AND METHODS FOR MODULATING SPLICING NOTTINGHAM, KYLE GREGORY 1621 Other Final Rejection 30d Pending Aug 26, 2022

Managing Remix Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month